从实验室到临床
从血癌到实体瘤
从癌症到自身免疫病
CAR-T疗法正以前所未有的速度，
重塑我们对“治愈”二字的理解。
本期海外名师大讲堂邀请到CAR-T细胞治疗领域的奠基人、宾夕法尼亚大学终身教授Carl H. June院士，带来题为 “CAR-T: Present and Future Prospects” 的学术盛宴。
CAR-T: Present and Future Prospects
CAR-T细胞治疗的现在与未来
Carl H. June
宾夕法尼亚大学终身教授
细胞免疫治疗中心主任
美国国家科学院、国家医学院、艺术与科学院三院院士
应颂敏教授
医学院常务副院长
黄河教授
医学院附属第一医院
2025年11月20日（周四）14:00
紫金港校区医学院仲兰报告厅
Prof. June's research team established the novel therapy with genetically engineered T cells. The treatment has been approved by the US FDA in 2017 as tisagenlecleucel for leukemia and lymphoma. Chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment in the 21st century, providing innovative solutions and life-saving therapies for previously untreatable diseases. This approach has shown remarkable success in treating various hematological malignancies and is now expanding into clinical trials for solid tumors, as well as infectious and autoimmune diseases. This seminar highlights the key milestones in CAR-T cell evolution, addresses remaining challenges in the field, and explores future directions and advances in the field, aiming to maximize efficacy, minimize toxicity, and broaden therapeutic applications.
